LataMed AI Corp. (OTC: LMED), a healthcare technology company specializing in digital health infrastructure for Latin America, announced that its mobile healthcare application has entered the final development stage, with testing and optimization underway ahead of a planned release on the Apple App Store and Google Play. The company expects to submit the app for distribution within weeks, subject to platform review, marking a shift from development to public availability.
This transition is a critical milestone for LataMed AI, as the app is designed to serve as the primary mobile gateway to its digital healthcare ecosystem. It will offer users a convenient interface to access supported services, digital tools, and future functionalities, including patient-facing tools, provider interaction, digital communications, and healthcare coordination. The company emphasizes that mobile accessibility is vital in Latin America, where smartphones are a primary means of accessing digital services. By launching on both major platforms, LataMed AI aims to provide a direct and accessible entry point to its ecosystem, establishing a scalable foundation for future expansion.
Dr. Kevin Rodan Levy, CEO of LataMed AI, highlighted the importance of this development: "Our mobile application is now moving from development toward deployment, and we believe we are approaching an important milestone for LataMed AI. Our team is completing final testing and preparation, and we expect the app to be available through the Apple App Store and Google Play in the coming weeks, subject to platform review." He added, "Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building."
The app's launch supports LataMed AI's broader strategy to connect patients, healthcare professionals, pharmacies, insurers, payment providers, and wellness organizations in an integrated digital environment. The company continues to develop AI-supported technologies, including CardioAI, PulmoAI, and NeuroAI, which are intended to assist healthcare professionals in evaluating cardiovascular, pulmonary, and neurological health data. These technologies remain subject to regulatory approvals and commercial implementation.
Following the initial release, LataMed AI plans to iteratively add features and integrations, potentially including enhanced AI tools and additional user-facing services. The company will provide updates as it completes submission and platform review processes. For more information, visit https://latamed.ai or review SEC filings at www.sec.gov.
This announcement underscores LataMed AI's commitment to leveraging mobile technology to bridge healthcare gaps in Latin America, a region where digital health adoption is accelerating. By prioritizing mobile accessibility, the company aims to democratize access to quality healthcare information and services, potentially improving outcomes for millions. The app's success will depend on user adoption, regulatory compliance, and the seamless integration of AI-driven tools, but its imminent launch represents a tangible step toward a more connected and efficient healthcare system.
